ICT GROUP Announces 3-Year Contract With Collagenex Pharmaceuticals, Inc.; Company Hosting Siebel ePharma Sales Force Automation Software.

Business Editors/Hi-Tech Writers

LANGHORNE, Pa.--(BUSINESS WIRE)--Dec. 11, 2001

ICT GROUP, INC. (NASDAQ:ICTG), a leading global provider of customer relationship management (CRM) solutions, announced today it has signed a 3-year contract with CollaGenex Pharmaceuticals, Inc. (NASDAQ: CGPI), a specialty pharmaceutical company providing innovative medical therapies to the dental market.

Under the terms of the agreement, ICT GROUP is supporting CollaGenex's staff of approximately 120 professional sales representatives and managers with hosted Siebel ePharma software for more streamlined and optimized multi-channel pharmaceutical sales. ICT GROUP's sales force solution, using software produced by Siebel Systems, Inc. (NASDAQ: SEBL), is designed specifically to increase pharmaceutical sales' productivity and efficiency, allowing representatives to coordinate product sample orders, shipments and transfers as well as inventory management and authorized signature capture and retrieval, from their handheld PC devices.

"We are pleased to be supporting CollaGenex in this most important sales force automation initiative," said John J. Brennan, Chairman and Chief Executive Officer of ICT GROUP. "Our hosted sales force solution provides CollaGenex with the ability to focus on their commitment to product and service quality delivery while helping to ensure that they meet or exceed their strategic growth and sales expansion objectives."

"ICT GROUP's experience hosting and implementing Siebel software for the pharmaceutical market provides CollaGenex with a powerful tool to dramatically enhance their sales activities," according to Timothy F. Kowalski, President of ICT GROUP CRM Technology Ventures. "The Siebel ePharma software, which resides on ICT GROUP's centralized database server, is part of the Company's contact management IT infrastructure designed to capture and track customer information from multiple communication channels in a single, unified knowledge base," Kowalski continued.

ICT GROUP is also providing technical support/help desk services, assisting CollaGenex's sales force with the installation, remote access and overall use of the sales force automation product.

"The decision to implement ICT GROUP's sales force solution using Siebel software was a logical choice in bringing our business development initiatives to the next level," said Neal Stone, Director of Sales Administration for CollaGenex. "This flexible, cost-effective solution gives us access to the best CRM applications, systems infrastructure and database technologies available while at the same time receiving professional IT support and leveraging ICT GROUP's expertise. We feel this is a winning combination that will increase sales force efficiency and productivity thus resulting in higher sales and company profitability."

ICT GROUP and CollaGenex both operate their corporate headquarters in Bucks County, Pa. Both companies were also recognized this year by Deloitte and Touche as one of the 50 Fastest Growing Technology Companies in Eastern Pennsylvania.

ABOUT COLLAGENEX:

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on providing innovative medical therapies to the dental market. The Company's lead product, Periostat(R), was approved by the FDA in September 1998 and is the first and only pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues. Periostat is marketed to the dental community by CollaGenex through a professional pharmaceutical sales force composed of approximately 120 sales representatives and managers. Currently, the Company's dental sales force is also marketing Atridox(R), an Atrix Laboratories product to treat adult periodontitis, Atrisorb(R), an Atrix guided tissue regeneration product, and Vioxx(R), a Merck & Co. drug that CollaGenex co-promotes for the treatment of acute dental pain.

Research has shown that the enzyme suppression technology underlying Periostat may also be applicable to other diseases involving destruction of the body's connective tissues, including cancer metastases (Metastat) and a broad range of inflammatory diseases. CollaGenex is developing a series of novel, proprietary compounds known as IMPACS (Inhibitors of Multiple Proteases and Cytokines) to address these applications. The Company intends to pursue further research and development of these technologies primarily through partnerships with third parties.

To receive additional information about CollaGenex, please visit the company's website at www.collagenex.com.

ABOUT ICT GROUP:

ICT GROUP, headquartered in Langhorne, Pa., is a leading global provider of integrated customer relationship management (CRM) solutions. The company helps clients identify, acquire, retain, service, measure and maximize the lifetime value of their customer relationships. The company manages CRM service operations in the U.S., Europe, Canada and Australia from which it supports domestic and multinational corporations and institutions, primarily in the financial, insurance, telecommunications, healthcare, information technology, media, energy and hospitality industries. ICT GROUP also provides targeted database modeling and multi-media detailing for the pharmaceutical industry through its recently launched proprietary sales optimization program, Direct Response Medical Detailing (DrMDSM). In addition to the hosted solutions described in this release, ICT GROUP also offers its CRM solutions on a fully outsourced basis as well as on a co-sourced basis, in conjunction with ICT GROUP 's fully compatible Web-enabled customer service operations. To learn more about ICT GROUP, visit the company's website at www.ictgroup.com.

This press release contains certain forward-looking statements that are subject to substantial risks and uncertainties. Whenever possible, forward-looking statements are preceded by, followed by or include the words "believes," "intends," "anticipates" or similar expressions which speak only as of the date the statement is made. ICT GROUP assumes no obligation to update any such forward-looking statements. For such statements, ICT GROUP claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual events or results of operation and financial condition may differ materially from those discussed in the forward-looking statements as a result of various factors, including without limitation, those discussed in ICT GROUP's annual report on Form 10-K for the year ended December 31, 2000, and other documents such as Form 10-Q and 8-K reports filed by ICT GROUP with the Securities and Exchange Commission. Although ICT GROUP believes that the expectations reflected in such forward-looking statements are reasonable there can be no assurance that such expectations will prove to be correct. Important factors that could cause actual results to differ materially from ICT GROUP's expectations may include, but are not limited to the following, many of which are outside ICT GROUP's control: customer demand for client's product, the client's budgets and plans, interest rates and other conditions affecting the client's industry, unanticipated labor, contract or technical difficulties, identifying and opening planned contact centers within timeframes necessary to meet client demands, reliance on strategic partners, industry and government regulation, reliance on telecommunications and computer technology, general and local economic conditions, and competitive pressures in ICT GROUP's industry.